BioStock:Abliva increases awareness of mitochondrial diseases

As the world observes Mitochondrial Disease Week, the spotlight is on the debilitating symptom of fatigue that plagues people with mitochondrial disease. Lund-based biotech company Abliva is at the forefront of this battle with its drug candidate KL1333, currently in a global phase II study. BioStock contacted Abliva’s Chief Medical Officer Magnus Hansson to learn more about the company’s work in close cooperation with patient organisations.

Read the article at biostock.se:

https://www.biostock.se/en/2023/09/abliva-increases-awareness-of-mitochondrial-diseases/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/